Abstract 3827: Bispecific antibodies with an anti-PD-1 backbone for cancer therapy generate enhanced immune activity

PD-1 antibody combination therapy shows great promise to further enhance clinical efficacy of PD-1 antibody. Bispecific antibody represents an emerging platform that allows simultaneous targeting of multiple pathways employing a single agent. Here we present a series of bispecific antibodies using anti-PD-1 antibody as backbone, including PD-1/CTLA-4 and PD-1/VEGF bispecific antibodies, which target additional immune suppressive pathways to further enhance cancer immunity. These include complementary check point pathway and suppression of dendritic cell maturation and antigen presentation. Clinical candidates for these projects have been selected demonstrating superior immune enhancing activity in preclinical study. These bispecific antibodes are designed based on Akeso Tetrabody platform, which has demonstrated robust developability properties. Akeso PD-1/CTLA-4 bispecific antibody AK104 has entered clinical trial for advanced solid tumors (ClinicalTrials.gov Identifier: NCT03261011). Citation Format: Baiyong Li, Zhaoliang Huang, Xinghua Pang, Tingting Zhong, Na Chen, Max Wang, Xiaoping Jin, Dennis Xia, Peng Zhang, Michelle Yu Xia. Bispecific antibodies with an anti-PD-1 backbone for cancer therapy generate enhanced immune activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3827.